Risankizumab: Mechanism of action, clinical and translational science

Risankizumab: Mechanism of action, clinical and translational science

Abstract Risankizumab is a high‐affinity neutralizing anti‐interleukin (IL)‐23 monoclonal antibody marketed in over 40 countries across the globe to treat several inflammatory diseases, such as plaque psoriasis (PsO), psoriatic arthritis (PsA), and Crohn's disease (CD). This paper reviews the r...

Full description

Bibliographic Details
Main Authors: Yinuo Pang, Ronilda D'Cunha, Insa Winzenborg, Geertruida Veldman, Valerie Pivorunas, Kori Wallace
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13706

Internet

https://doi.org/10.1111/cts.13706

Similar Items